Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8288281 | 0.86 | SSTR5 (0.38) | NR4A2KCNH2NPY1RHTR1ASLC6A2 | |
| SCHEMBL8287184 | 0.86 | SSTR5 (0.43) | NR4A2KCNH2NPY1RHTR1ASLC6A2 | |
| SCHEMBL14169117 | 0.85 | CCR8 (0.49) | PRMT5HSD17B10 | |
| SCHEMBL1495258 | 0.83 | SSTR5 (0.40) | NR4A2KCNH2NPY1RHTR1ASLC6A2 | |
| SCHEMBL8287213 | 0.83 | NPY1R (0.45) | NR4A2KCNH2NPY1RSSTR5 | |
| SCHEMBL1495215 | 0.83 | SSTR5 (0.39) | NR4A2KCNH2NPY1RHTR1ASLC6A2 | |
| SCHEMBL8287092 | 0.82 | KCNH2 (0.47) | NR4A2KCNH2SOS1NPY1RSSTR5 | |
| SCHEMBL14173543 | 0.76 | KCNH2 (0.57) | NR4A2KCNH2SOS1HTR1ASLC6A2 | |
| SCHEMBL12532504 | 0.72 | BRD4 (0.48) | NR4A2KCNH2HTR1ASLC6A2SLC6A4 | |
| SCHEMBL11265895 | 0.71 | KCNH2 (0.83) | NR4A2KCNH2SOS1HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723136-B1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2011-03-09 | — | — | EP | disclosed |
| US-20080146613-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146613-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-06-19 | — | — | US | disclosed |
| US-7355051-B2 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2008-04-08 | — | — | US | disclosed |
| US-7355051-B2 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2008-04-08 | — | — | US | disclosed |
| US-20070093659-A1 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093659-A1 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-04-26 | — | — | US | disclosed |
| WO-2005058873-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093659-A1 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | NQO2, NOX1, NOX3 | NR4A2 388/4885KCNH2 347/4885SOS1 3203/4885 |
| US-20080146613-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | NQO2, NOX3, NOX1 | NR4A2 311/4885KCNH2 487/4885SOS1 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.